<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01680068</url>
  </required_header>
  <id_info>
    <org_study_id>2012815b</org_study_id>
    <nct_id>NCT01680068</nct_id>
  </id_info>
  <brief_title>Air Tamponade in Macular Hole Surgery</brief_title>
  <official_title>Air Tamponade in Macular Hole Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helse Stavanger HF</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Macular hole is a hole formation which takes place in the center of the retina. Such a hole
      needs surgical steps in order to close. Closure of the macular hole will lead to a
      substantially improvement of vision in most cases. Following macular hole surgery a tamponade
      of intraocular gas is normally injected in order to keep the macula dry for the postoperative
      period. Postoperative face down position for a week was earlier standard. Several authors
      report of good closure rates with both air tamponade or lack of face down positioning. In
      this study standard pars plana vitrectomy with peeling of the internal limiting membrane
      (ILM) will be performed. The gas tamponade will be replaced by air. Postoperative face down
      positioning will not be used.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Closure rate of macular hole</measure>
    <time_frame>1 month after enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Closure rate in macular holes larger than 400 micrometer</measure>
    <time_frame>1 month after enrollment</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Visual gain after 6 months of follow up</measure>
    <time_frame>6 months after enrollment</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Macular Hole</condition>
  <arm_group>
    <arm_group_label>Pars plana vitrectomy and postoperative air tamponade</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pars plana vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pars plana vitrectomy and postoperative air tamponade</intervention_name>
    <description>Pars plans vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.</description>
    <arm_group_label>Pars plana vitrectomy and postoperative air tamponade</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic stage 2 - 4 macular hole

          -  Duration of symptoms ≤ 36 months

          -  Informed consent

        Exclusion Criteria:

          -  Previous vitreomacular surgery

          -  Myopia ≥ 6 diopters

          -  Ocular trauma

          -  Disease affecting visual function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vegard Forsaa, MD</last_name>
    <role>Study Director</role>
    <affiliation>Helse Stavanger HF</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stavanger University Hospital, Department of Ophthalmology</name>
      <address>
        <city>Stavanger</city>
        <zip>4016</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2012</study_first_submitted>
  <study_first_submitted_qc>September 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2012</study_first_posted>
  <last_update_submitted>December 4, 2013</last_update_submitted>
  <last_update_submitted_qc>December 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Macular hole</keyword>
  <keyword>Vitreoretinal surgery</keyword>
  <keyword>Macular surgery</keyword>
  <keyword>Air tamponade</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Perforations</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

